Edition:
United States

Akers Biosciences Inc (AKR.L)

AKR.L on London Stock Exchange

75.00GBp
11:02am EDT
Change (% chg)

0.00 (+0.00%)
Prev Close
75.00
Open
75.00
Day's High
--
Day's Low
--
Volume
2,642
Avg. Vol
692
52-wk High
255.00
52-wk Low
65.00

Chart for

About

Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including... (more)
No analyst recommendations are available for .

Overall

Beta: 1.75
Market Cap(Mil.): £6.04
Shares Outstanding(Mil.): 8.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Akers Biosciences Inc Q2 revenue up 25 pct

* Qtrly loss before income tax reduced by 34% to $666,647 Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Akers Biosciences Q2 revenue $1.2 million

* Q2 revenue $1.2 million Source text for Eikon: Further company coverage:

Aug 03 2017

BRIEF-Akers Biosciences reports earnings for fiscal year 2016

* Akers Biosciences - Expect 2017 to be characterized by further growth in flagship PIFA Heparin PF/4 rapid assay product line, sales of rapid cholesterol test Source text for Eikon: Further company coverage:

Apr 11 2017

BRIEF-Akers Biosciences to commercialize heparin PF4 rapid test in Puerto Rico

* Akers Biosciences to commercialize heparin PF4 rapid test in Puerto Rico Source text for Eikon: Further company coverage:

Apr 10 2017

BRIEF-Empery Asset Management reports 8.45 pct passive stake in Akers Biosciences

* Empery Asset Management LP reports 8.45 percent passive stake in Akers Biosciences Inc, as of March 30, 2017 - sec filing Source text - http://bit.ly/2nTrng1 Further company coverage:

Apr 07 2017

BRIEF-Akers Biosciences files for non-timely 10-K - SEC filing

* Akers Biosciences Inc files for non-timely 10-K - SEC filing

Mar 31 2017

BRIEF-Akers Biosciences announces a $2 million private placement

* Akers Biosciences Inc - Akers Bio will issue 1.4 million shares at a price of $1.40 per share Source text for Eikon: Further company coverage:

Mar 30 2017

BRIEF-Akers Biosciences begins selling rapid cholesterol test

* Akers Biosciences begins selling rapid cholesterol test through distribution agreement with first check Source text for Eikon: Further company coverage:

Mar 28 2017

Earnings vs. Estimates